vs
Apellis Pharmaceuticals, Inc.（APLS）与NATIONAL PRESTO INDUSTRIES INC（NPK）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是NATIONAL PRESTO INDUSTRIES INC的1.2倍（$199.9M vs $164.0M），NATIONAL PRESTO INDUSTRIES INC同比增速更快（21.7% vs -5.9%），NATIONAL PRESTO INDUSTRIES INC自由现金流更多（$12.4M vs $-14.3M），过去两年NATIONAL PRESTO INDUSTRIES INC的营收复合增速更高（46.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
National Presto Industries创始于1905年，总部位于美国威斯康星州欧克莱尔，历经多次更名后于1953年确定现用名。该公司最初生产商用及后续家用压力锅，自1939年起推出小型家用烹饪电器，1969年在纽约证券交易所上市。
APLS vs NPK — 直观对比
营收规模更大
APLS
是对方的1.2倍
$164.0M
营收增速更快
NPK
高出27.7%
-5.9%
自由现金流更多
NPK
多$26.7M
$-14.3M
两年增速更快
NPK
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $164.0M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 16.9% |
| 营业利润率 | -25.6% | 11.4% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 21.7% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNPK
| Q4 25 | $199.9M | $164.0M | ||
| Q3 25 | $458.6M | $115.5M | ||
| Q2 25 | $178.5M | $120.4M | ||
| Q1 25 | $166.8M | $103.6M | ||
| Q4 24 | $212.5M | $134.7M | ||
| Q3 24 | $196.8M | $91.8M | ||
| Q2 24 | $199.7M | $85.1M | ||
| Q1 24 | $172.3M | $76.7M |
净利润APLSNPK
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $5.3M | ||
| Q2 25 | $-42.2M | $5.2M | ||
| Q1 25 | $-92.2M | $7.6M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $8.1M | ||
| Q2 24 | $-37.7M | $6.1M | ||
| Q1 24 | $-66.4M | $6.6M |
毛利率APLSNPK
| Q4 25 | — | 16.9% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 15.4% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | — | 24.3% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | — | 17.3% | ||
| Q1 24 | — | 18.1% |
营业利润率APLSNPK
| Q4 25 | -25.6% | 11.4% | ||
| Q3 25 | 48.7% | 5.6% | ||
| Q2 25 | -18.6% | 5.1% | ||
| Q1 25 | -50.0% | 8.8% | ||
| Q4 24 | -12.3% | 17.3% | ||
| Q3 24 | -24.0% | 10.0% | ||
| Q2 24 | -14.7% | 7.5% | ||
| Q1 24 | -36.0% | 8.2% |
净利率APLSNPK
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 4.6% | ||
| Q2 25 | -23.6% | 4.3% | ||
| Q1 25 | -55.3% | 7.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 8.8% | ||
| Q2 24 | -18.9% | 7.1% | ||
| Q1 24 | -38.5% | 8.6% |
每股收益（稀释后）APLSNPK
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $3.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $395.1M |
| 总资产 | $1.1B | $500.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSNPK
| Q4 25 | $466.2M | $3.8M | ||
| Q3 25 | $479.2M | $4.6M | ||
| Q2 25 | $370.0M | $4.8M | ||
| Q1 25 | $358.4M | $5.5M | ||
| Q4 24 | $411.3M | $22.7M | ||
| Q3 24 | $396.9M | $33.2M | ||
| Q2 24 | $360.1M | $53.4M | ||
| Q1 24 | $325.9M | $87.9M |
总债务APLSNPK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSNPK
| Q4 25 | $370.1M | $395.1M | ||
| Q3 25 | $401.2M | $379.8M | ||
| Q2 25 | $156.3M | $374.1M | ||
| Q1 25 | $164.2M | $368.6M | ||
| Q4 24 | $228.5M | $367.6M | ||
| Q3 24 | $237.1M | $346.6M | ||
| Q2 24 | $264.3M | $338.1M | ||
| Q1 24 | $266.7M | $331.6M |
总资产APLSNPK
| Q4 25 | $1.1B | $500.7M | ||
| Q3 25 | $1.1B | $503.8M | ||
| Q2 25 | $821.4M | $471.9M | ||
| Q1 25 | $807.3M | $455.3M | ||
| Q4 24 | $885.1M | $453.4M | ||
| Q3 24 | $901.9M | $428.9M | ||
| Q2 24 | $904.5M | $418.1M | ||
| Q1 24 | $831.9M | $417.5M |
负债/权益比APLSNPK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $13.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $12.4M |
| 自由现金流率自由现金流/营收 | -7.1% | 7.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-36.2M |
8季度趋势，按日历期对齐
经营现金流APLSNPK
| Q4 25 | $-14.2M | $13.9M | ||
| Q3 25 | $108.5M | $-24.6M | ||
| Q2 25 | $4.4M | $-10.9M | ||
| Q1 25 | $-53.4M | $12.5M | ||
| Q4 24 | $19.4M | $-7.6M | ||
| Q3 24 | $34.1M | $-17.5M | ||
| Q2 24 | $-8.3M | $-33.9M | ||
| Q1 24 | $-133.0M | $5.6M |
自由现金流APLSNPK
| Q4 25 | $-14.3M | $12.4M | ||
| Q3 25 | $108.3M | $-24.7M | ||
| Q2 25 | $4.4M | $-13.4M | ||
| Q1 25 | $-53.4M | $-10.5M | ||
| Q4 24 | $19.3M | $-11.3M | ||
| Q3 24 | — | $-20.3M | ||
| Q2 24 | $-8.4M | $-34.5M | ||
| Q1 24 | $-133.3M | $5.2M |
自由现金流率APLSNPK
| Q4 25 | -7.1% | 7.6% | ||
| Q3 25 | 23.6% | -21.4% | ||
| Q2 25 | 2.5% | -11.1% | ||
| Q1 25 | -32.0% | -10.2% | ||
| Q4 24 | 9.1% | -8.4% | ||
| Q3 24 | — | -22.1% | ||
| Q2 24 | -4.2% | -40.6% | ||
| Q1 24 | -77.3% | 6.7% |
资本支出强度APLSNPK
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 2.0% | ||
| Q1 25 | 0.0% | 22.2% | ||
| Q4 24 | 0.0% | 2.7% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 0.8% | ||
| Q1 24 | 0.2% | 0.5% |
现金转化率APLSNPK
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | -4.63× | ||
| Q2 25 | — | -2.12× | ||
| Q1 25 | — | 1.64× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2.16× | ||
| Q2 24 | — | -5.58× | ||
| Q1 24 | — | 0.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NPK
暂无分部数据
